116 related articles for article (PubMed ID: 30860451)
1. Neurodegeneration of the Substantia Nigra after Ipsilateral Infarct: MRI R2* Mapping and Relationship to Clinical Outcome.
Linck PA; Kuchcinski G; Munsch F; Griffier R; Lopes R; Okubo G; Sagnier S; Renou P; Asselineau J; Perez P; Dousset V; Sibon I; Tourdias T
Radiology; 2019 May; 291(2):438-448. PubMed ID: 30860451
[TBL] [Abstract][Full Text] [Related]
2. Thalamic alterations remote to infarct appear as focal iron accumulation and impact clinical outcome.
Kuchcinski G; Munsch F; Lopes R; Bigourdan A; Su J; Sagnier S; Renou P; Pruvo JP; Rutt BK; Dousset V; Sibon I; Tourdias T
Brain; 2017 Jul; 140(7):1932-1946. PubMed ID: 28549087
[TBL] [Abstract][Full Text] [Related]
3. Differential Effect of Iron and Myelin on Susceptibility MRI in the Substantia Nigra.
Lee H; Cho H; Lee MJ; Kim TH; Roh J; Lee JH
Radiology; 2021 Dec; 301(3):682-691. PubMed ID: 34609198
[TBL] [Abstract][Full Text] [Related]
4. Substantia Nigra Volumetry with 3-T MRI in De Novo and Advanced Parkinson Disease.
Vitali P; Pan MI; Palesi F; Germani G; Faggioli A; Anzalone N; Francaviglia P; Minafra B; Zangaglia R; Pacchetti C; Gandini Wheeler-Kingshott CAM
Radiology; 2020 Aug; 296(2):401-410. PubMed ID: 32544035
[TBL] [Abstract][Full Text] [Related]
5. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
[TBL] [Abstract][Full Text] [Related]
6. High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra.
Zhong Z; Merkitch D; Karaman MM; Zhang J; Sui Y; Goldman JG; Zhou XJ
Radiology; 2019 Apr; 291(1):149-157. PubMed ID: 30777809
[TBL] [Abstract][Full Text] [Related]
7. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.
Gorell JM; Ordidge RJ; Brown GG; Deniau JC; Buderer NM; Helpern JA
Neurology; 1995 Jun; 45(6):1138-43. PubMed ID: 7783878
[TBL] [Abstract][Full Text] [Related]
8. In vivo USPIO-enhanced MR signal characteristics of secondary degeneration in the ipsilateral substantia nigra after middle cerebral artery occlusion at 3T.
Yang YM; Feng XY; Yin le K; Li CC; Li AN; Jia J; Wang XL; Du ZG; Jin LX
J Neuroradiol; 2013 Jul; 40(3):198-203. PubMed ID: 23428242
[TBL] [Abstract][Full Text] [Related]
9. Impaired glymphatic system in secondary degeneration areas after ischemic stroke in rats.
Lin L; Hao X; Li C; Sun C; Wang X; Yin L; Zhang X; Tian J; Yang Y
J Stroke Cerebrovasc Dis; 2020 Jul; 29(7):104828. PubMed ID: 32404284
[TBL] [Abstract][Full Text] [Related]
10. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease.
Khedher L; Bonny JM; Marques A; Durand E; Pereira B; Chupin M; Vidal T; Chassain C; Defebvre L; Carriere N; Fraix V; Moro E; Thobois S; Metereau E; Mangone G; Vidailhet M; Corvol JC; Lehéricy S; Menjot de Champfleur N; Geny C; Spampinato U; Meissner W; Frismand S; Schmitt E; Doé de Maindreville A; Portefaix C; Remy P; Fénelon G; Luc Houeto J; Colin O; Rascol O; Peran P; Durif F;
Neuroimage Clin; 2022; 36():103231. PubMed ID: 36279753
[TBL] [Abstract][Full Text] [Related]
11. Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease.
Arribarat G; Pasternak O; De Barros A; Galitzky M; Rascol O; Péran P
Parkinsonism Relat Disord; 2019 Aug; 65():146-152. PubMed ID: 31182373
[TBL] [Abstract][Full Text] [Related]
12. Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
Du G; Lewis MM; Sica C; He L; Connor JR; Kong L; Mailman RB; Huang X
Mov Disord; 2018 Sep; 33(9):1423-1431. PubMed ID: 29756399
[TBL] [Abstract][Full Text] [Related]
13. 3D texture analyses within the substantia nigra of Parkinson's disease patients on quantitative susceptibility maps and R2
Li G; Zhai G; Zhao X; An H; Spincemaille P; Gillen KM; Ku Y; Wang Y; Huang D; Li J
Neuroimage; 2019 Mar; 188():465-472. PubMed ID: 30578927
[TBL] [Abstract][Full Text] [Related]
14. Secondary neurodegeneration of ipsilateral substantia nigra in acute ischemic stroke.
Zedde M; Grisendi I; Assenza F; Napoli M; Moratti C; Valzania F; Pascarella R
Neurol Sci; 2023 Nov; 44(11):4099-4102. PubMed ID: 37526798
[TBL] [Abstract][Full Text] [Related]
15. Is hyperhomocysteinemia associated with the structural changes of the substantia nigra in Parkinson's disease? A two-year follow-up study.
Zhang G; Zhang C; Wang Y; Wang L; Zhang Y; Xie H; Lu J; Nie K
Parkinsonism Relat Disord; 2019 Mar; 60():46-50. PubMed ID: 30316729
[TBL] [Abstract][Full Text] [Related]
16. Degeneration of the ipsilateral substantia nigra after striatal infarction: evaluation with MR imaging.
Ogawa T; Okudera T; Inugami A; Noguchi K; Kado H; Yoshida Y; Uemura K
Radiology; 1997 Sep; 204(3):847-51. PubMed ID: 9280270
[TBL] [Abstract][Full Text] [Related]
17. Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum.
Nakane M; Teraoka A; Asato R; Tamura A
Stroke; 1992 Mar; 23(3):328-32. PubMed ID: 1542891
[TBL] [Abstract][Full Text] [Related]
18. Functional connectivity disruption of the substantia nigra associated with cognitive impairment in acute mild traumatic brain injury.
Lu L; Li F; Ma Y; Chen H; Wang P; Peng M; Chen YC; Yin X
Eur J Radiol; 2019 May; 114():69-75. PubMed ID: 31005180
[TBL] [Abstract][Full Text] [Related]
19. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
